cGMP in the vasculature

Barbara Kathryn Kemp, Harald Schmidt

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

37 Citations (Scopus)

Abstract

Cyclic guanosine 3 , 5 -monophosphate (cGMP) plays an integral role in the control of vascular function. Generated from guanylate cyclases in response to the endogenous ligands, nitric oxide (NO) and natriuretic peptides (NPs), cGMP influences a number of vascular cell types and regulates vasomotor tone, endothelial permeability, cell growth and differentiation, as well as platelet and blood cell interactions. Reciprocal regulation of the NO-cGMP and NP-cGMP pathways is evident in the vasculature such that one cGMP generating system may compensate for the dysfunction of the other. Indeed, aberrant cGMP production and/or signalling accompanies many vascular disorders such as hypertension, atherosclerosis, coronary artery disease and diabetic complications. This chapter highlights the main vascular functions of cGMP, its role in disease and the resulting current and potential therapeutic applications. With respect to pulmonary hypertension, heart failure and erectile dysfunction, as well as cGMP signal transduction, the reader is specifically referred to other dedicated chapters.
Original languageEnglish
Title of host publicationcGMP: Generators, Effectors and Therapeutic Implications
EditorsH H H W Schmidt, F Hofmann, J-P Stasch
Place of PublicationHeidelberg Berlin
PublisherSpringer
Pages447 - 467
Number of pages21
Edition191
ISBN (Print)9783540689607
Publication statusPublished - 2009

Cite this